Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
11. |
ECCT/25/05/06 | Hibiscus 2 - Site 254 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Doreen Mutua Site(s) in Kenya 1. Site 254 - Gertrude\'s Children\'s Hospital (Nairobi City county) |
View |
12. |
ECCT/25/05/05 | Hibiscus 2 - Site 252 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county) |
View |
13. |
ECCT/25/05/04 | Floral roll over study An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Bernhard Ogutu Site(s) in Kenya 1. KEMRI Kondele Children\'s Hospital (Kisumu county) 2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 3. Gertrudes Childrens Hospital (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 6. KEMRI WALTER REED KERICHO (Kericho county) 7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) |
View |
14. |
ECCT/25/05/03 | Hibiscus 2 - Site 253 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Site 253 - International Cancer Institute (Uasin Gishu county) |
View |
15. |
ECCT/25/05/02 | Hibiscus 2 - Site 251 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county) |
View |